The Region 4 Stork (R4S) Collaborative Project - Insights
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
The Region 4 Stork (R4S) Collaborative Project - Insights
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
The Region 4 Stork (R4S) Collaborative Project - Insights
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
The Region 4 Stork (R4S) Collaborative Project - Insights
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
The Region 4 Stork (R4S) Collaborative Project - Insights
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
The Region 4 Stork (R4S) Collaborative Project - Insights
This is a 6-part series describing the products and clinical tools of a laboratory quality improvement project called Region 4 Stork, or R4S.
New Tests Launched in August - Insights
In August 2017, Mayo Medical Laboratories announced a new test along with numerous reference value changes, obsolete tests, and algorithm changes.
TPMT Testing in Treatment of Inflammatory Bowel Disease [Test in Focus] - Insights
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.
New Tests Launched in February - Insights
In February 2018, Mayo Medical Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Mayo Clinic Laboratory and Pathology Research Roundup: January 9 - Insights
This week's research roundup feature: To describe a 41-year-old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin-1 receptor...